The global implantable cardioverter defibrillator (ICD) market was valued at US$ 3.6 billion in 2022. It is projected to grow at a CAGR of 5.6% from 2023 to 2031, reaching over US$ 5.8 billion by 2031.
Analysts predict that the rise in prevalence of cardiovascular diseases and associated risk factors, such as hypertension and heart failure, will be key drivers for the global ICD market during the forecast period. The increasing demand for effective cardiac rhythm management devices, particularly ICDs, due to the aging global population and the growing incidence of these conditions, is expected to fuel industry growth. Additionally, the adoption of remote monitoring and telehealth solutions in healthcare is anticipated to further bolster the global ICD market.
Download Sample PDF: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13826&utm_source=organic&utm_campaign=MansiR_organic
The implantable cardioverter defibrillator (ICD) is a small electronic device surgically implanted beneath the skin, typically near the collarbone. It continuously monitors the heart’s electrical activity and delivers therapeutic interventions when needed.
Its primary function is to detect and treat potentially fatal arrhythmias, such as ventricular fibrillation and ventricular tachycardia, by delivering precisely calibrated electrical shocks to restore the heart’s normal rhythm.
The implantation procedure is generally safe and well-tolerated, performed under local anesthesia with sedation. The device’s leads are threaded through veins into the heart chambers, allowing for accurate sensing of electrical signals.
Key Players:
Boston Scientific Corporation, BIOTRONIK., Medtronic, LivaNova, Abbott, and MicroPort.
Segmentation:
- Product
- Transvenous Implantable Cardiac Defibrillators (T-ICDs)
- Cardiac Resynchronization Therapy (CRT)
- Dual Chamber ICDs
- Single Chamber ICDs
- Subcutaneous Implantable Cardiac Defibrillators (S-ICD)
- Transvenous Implantable Cardiac Defibrillators (T-ICDs)
- End-user
- Hospitals & Clinics
- Ambulatory Surgery Centers
- Others
Surge in Demand for Transvenous implantable Cardiac Defibrillators
In 2022, the transvenous implantable cardiac defibrillators (T-ICDs) segment held the largest share in the global implantable cardioverter defibrillator market. T-ICDs, being the traditional and widely utilized type of implantable defibrillators, offer a reliable method for managing life-threatening arrhythmias. Their dominance in the market is attributed to their extensive clinical history and proven effectiveness in preventing sudden cardiac death, instilling confidence among healthcare providers and patients alike.
T-ICDs, implanted via transvenous leads threaded into the heart, ensure accurate sensing of cardiac electrical activity and prompt delivery of electrical shocks when needed. This transvenous approach enables precise lead placement, enhancing the detection and therapy delivery for various arrhythmias, thus contributing to their widespread adoption.
Moreover, T-ICDs boast additional features such as dual-chamber therapy and cardiac resynchronization therapy (CRT). Unlike subcutaneous implantable cardioverter defibrillators (S-ICDs), T-ICDs can monitor both ventricular and atrial rhythms, offering comprehensive monitoring and treatment options. Furthermore, the integration of CRT in T-ICDs provides a holistic treatment approach for patients with arrhythmias and heart failure, underscoring their significance in cardiac rhythm management.
Key Developments:
- In February 2023, Medtronic plc received the CE Mark for the Epsila EV MRI SureScan defibrillation system and the Aurora EV-ICD MRI SureScan lead. These advanced technologies are designed to effectively address rapid and potentially life-threatening heart rhythms that can result in sudden cardiac arrest.
- In November 2022, AtaCor Medical, Inc., a San Clemente-based medical device manufacturer, announced successful completion of its 2nd human clinical study on the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System.
- AtaCor Medical is currently in the process of developing a groundbreaking EV-ICD lead designed to administer both shock and pacing therapies to address life-threatening tachyarrhythmias. This innovative lead can be seamlessly connected to commercially available ICD pulse generators, offering a range of comprehensive treatment options.
- In February 2020, Abbott announced that it received the CE Mark for its latest Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. This achievement signifies a major milestone in providing advanced heart rhythm management capabilities and introducing a range of new benefits to individuals in Europe suffering from abnormal heart rhythms and heart failure.
Regions Covered:
North America(USA, Canada and Mexico)
Europe(UK, Germany, France and the Rest of Europe)
Asia Pacific(China, Japan, India, and the Rest of the Asia Pacific region)
South America(Brazil, Argentina and the Rest of South America)
Middle East and Africa(GCC and Rest of the Middle East and Africa)
Key Market Study Points
- Analysis of market dynamics, including drivers, challenges, opportunities, and trends.
- Assessment of market size and growth potential across different segments and regions.
- Evaluation of competitive landscape, including key players, market share, and strategic initiatives.
- Examination of regulatory landscape and its impact on market dynamics.
- Identification of emerging technologies and their potential to disrupt the market.
Browse More Reports by TMR:
Global Advanced Energy Storage Market Size Estimated at US$ 2.08 Bn by 2031
Self-Injection Device Market Estimated to Reach Value of US$ 11.3 Bn by 2026
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]
Follow Us: LinkedIn| Twitter| Blog | YouTube